Myositis registries and biorepositories: Powerful tools to advance clinical, epidemiologic and pathogenic research

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 724-741

  Rider, Lisa G ^a   Dankó, Katalin ^b   Miller, Frederick W ^a  

^a National Institute of Sciences   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Biorepository; Dermatomyositis; Idiopathic inflammatory myopathies; Inclusion body myositis; Juvenile dermatomyositis; Myositis autoantibody; Natural history; Phenotype; Polymyositis; Registry

Indexed keywords

AUTOIMMUNE DISEASE; CLINICAL DATA REPOSITORY; DERMATOMYOSITIS; DISEASE REGISTRY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INCLUSION BODY MYOSITIS; JUVENILE DERMATOMYOSITIS; MYOSITIS; OUTCOME ASSESSMENT; PHENOTYPE; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUPPORT GROUP; TREATMENT RESPONSE; PROGNOSIS; REGISTER; SEVERITY OF ILLNESS INDEX;

HUMANS; MYOSITIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84927794642     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000119     Document Type: Review

References (166)

1. Huber AM, Mamyrova G, Lachenbruch PA, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2014; 66:732-740.
2. Hashkes PJ, Wright BM, Lauer MS, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010; 62:599-608.
3. Ohta A, Nagai M, Nishina M, et al. Age at onset and gender distribution of systemic lupus erythematosus, polymyositis/dermatomyositis, and systemic sclerosis in Japan. Mod Rheumatol 2013; 23:759-764.
4. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56:255-286.
5. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
6. Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan.MuscleNerve 2012; 45:676-683.
7. Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 2012; 13:103.
8. Barnabe C, Joseph L, Belisle P, et al. Prevalence of autoimmune inflammatory myopathy in the first nations population of Alberta, Canada. Arthritis Care Res (Hoboken) 2012; 64:1715-1719.
9. Bernatsky S, Joseph L, Pineau CA, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis 2009; 68:1192-1196.
10. Tan JA, Roberts-Thomson PJ, Blumbergs P, et al. Incidence and prevalence of idiopathic inflammatory myopathies inSouth Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis 2013; 16:331-338.
11. Furst DE, Amato AA, Iorga SR, et al. Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population. Muscle Nerve 2012; 46:496-505.
12. Bernatsky S, Panopalis P, Pineau CA, et al. Healthcare costs of inflammatory myopathies. J Rheumatol 2011; 38:885-888.
13. Lundberg IE, Svensson J. Registries in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2013; 25:729-734.
14. Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al. Anti-PL-7 (antithreonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 2012; 91:206-211.
15. Miller FW, Cooper RG, Vencovsky J, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 2013; 65:3239-3247.
16. Betteridge Z, Tansley S, Gunawardena H, et al. Clinical phenotypes of Caucasian adult and juvenile dermatomyositis patients with anti-MDA5 autoantibodies [abstract]. Arthritis Rheum 2012; 64 (Suppl):S1673.
17. Chinoy H, Adimulam S, Marriage F, et al. Interaction of HLA-DRB1∗03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis 2012; 71:961-965.
18. Tjärnlund A, Bottai M, Rider LG, et al., The International Myositis Classification Criteria Project. Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies [abstract]. Arthritis Rheum 2012; 64 (Suppl):S323-S324.
19. Rider LG, Giannini EH, Harris-Love M, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003; 30:603-617.
20. Dugan EM, Huber AM, Miller FW, Rider LG. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009; 15:1.
21. O'Hanlon TP, Carrick DM, Arnett FC, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A,-B,-Cw,-DRB1 and-DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore) 2005; 84:338-349.
22. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A,-B,-Cw,-DRB1, and-DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85:111-127.
23. Rider LG, Lachenbruch PA, Monroe JB, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009; 60:3425-3435.
24. Feroz S, Ruperto N, Vencovsky J, et al. Developing international consensus definitions of improvement for adult and juvenile dermatomyositis and polymyositis. Arthritis Rheum 2013; 65 (Suppl):S844-S845.
25. Rider LG, Faiq A, Farhadi PN, et al. A58: demographics, clinical features and therapies of patients with juvenile dermatomyositis participating in a national myositis patient registry [abstract]. Arthritis Rheumatol 2014; 66 (Suppl): S86-S87.
26. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8:R13.
27. Chinoy H, Li CK, Platt H, et al. Genetic association study of NF-kappaB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. Rheumatology (Oxford) 2012; 51:794-799.
28. Seshadri R, Feldman BM, Ilowite N, et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008; 59:989-995.
29. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013; 65:2954-2962.
30. Hall JC, Casciola-Rosen L, Samedy LA, et al. Antimelanoma differentiationassociated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65:1307-1315.
31. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1∗11:01 in antihydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012; 64:1233-1237.
32. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statinassociated autoimmune myopathy. Arthritis Rheum 2011; 63:713-721.
33. Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012; 64:4087-4093.
34. Vancsa A, Gergely L, Ponyi A, et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 2010; 77:125-130.
35. Constantin T, Ponyi A, Orban I, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary: clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 2006; 39:223-232.
36. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008; 35:438-444.
37. Danko K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004; 83:35-42.
38. Vincze M, Der H, Kerekes G, et al. Decreased flow-mediated dilatation with increased arterial stiffness and thickness as early signs of atherosclerosis in polymyositis and dermatomyositis patients. Clin Rheumatol 2014. [Epub ahead of print]
39. Szodoray P, Alex P, Knowlton N, et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) 2010; 49:1867-1877.
40. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13:59-68.
41. Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferonregulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60:3436-3446.
42. Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve 2010; 41:581-592.
43. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013; 88:83-105.
44. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:25-34.
45. Wong D, Kea B, Pesich R, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012; 7:e29161.
46. Streicher K, Morehouse CA, Groves CJ, et al. The plasma cell signature in autoimmune disease. Arthritis Rheumatol 2014; 66:173-184.
47. Zhu W, Streicher K, Shen N, et al. Genomic signatures characterize leukocyte infiltration in myositis muscles. BMC Med Genomics 2012; 5:53.
48. Sarin KY, Chung L, Kim J, et al. Molecular profiling to diagnose a case of atypical dermatomyositis. J Invest Dermatol 2013; 133:2796-2799.
49. Muro Y, Sugiura K, Hoshino K, et al. Epidemiologic study of clinically amyopathic dermatomyositis and antimelanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 2011; 13:R214.
50. Muro Y, Ishikawa A, Sugiura K, Akiyama M. Clinical features of anti-TIF1-alpha antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-gamma or anti-Mi-2 autoantibodies. Rheumatology (Oxford) 2012; 51:1508-1513.
51. Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) 2012; 51:1181-1187.
52. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 2012; 51:800-804.
53. Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49:1726-1733.
54. Love LA, Weinberg CR, McConnaughey DR, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 2009; 60:2499-2504.
55. O'Hanlon TP, Rider LG, Gan L, et al. Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Res Ther 2011; 13:R69.
56. Volochayev R, Csako G, Wesley R, et al. Laboratory test abnormalities are common in polymyositis and dermatomyositis and differ among clinical and demographic groups. Open Rheumatol J 2012; 6:54-63.
57. O'Hanlon TP, Li Z, Gan L, et al. Plasma proteomic profiles from diseasediscordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases. Arthritis Res Ther 2011; 13:R181.
58. Ohta A, Nagai M, Nishina M, et al. Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod Rheumatol 2014; 24:477-480.
59. Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63:1961-1971.
60. Dimitri D, Benveniste O, Dubourg O, et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain 2006; 129:986-995.
61. Allenbach Y, Drouot L, Rigolet A, et al. Inconstant exposure to statin in autoimmune necrotizing myopathies associated with anti-HMGCR. Medicine (Baltimore) 2014; 93:150-157.
62. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134:3176-3184.
63. Allenbach Y, Chaara W, Rosenzwajg M, et al. Th1 response and systemic treg deficiency in inclusion body myositis. PLoS One 2014; 9:e88788.
64. Basnayake SK, Blumbergs P, Tan JA, et al. Inflammatory myopathy with anti-SRP antibodies: case series of a South Australian cohort. Clin Rheumatol 2014. [Epub ahead of print] Clinical characteristics and histology results of five anti-SRP positive male patients.
65. Ellis E, Ann TJ, Lester S, et al. Necrotizing myopathy: clinicoserologic associations. Muscle Nerve 2012; 45:189-194.
66. Das L, Blumbergs PC, Manavis J, Limaye VS. Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy. Appl Immunohistochem Mol Morphol 2013; 21:539-542.
67. Limaye V, Hakendorf P, Woodman RJ, et al. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J 2012; 42:191-198.
68. Limaye V, Luke C, Tucker G, et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013; 33:965-971.
69. de Souza FH, Shinjo SK. The high prevalence of metabolic syndrome in polymyositis. Clin Exp Rheumatol 2014; 32:82-87.
70. de Moraes MT, de Souza FH, de Barros TB, Shinjo SK. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hoboken) 2013; 65:793-799.
71. Wilton K, Bartholmai B, Kalra S, et al. Use of 'Computer-Aided Lung Informatics For Pathology Evaluation and Rating' software in high-resolution computed tomography in patients with idiopathic inflammatory myopathy and interstitial lung disease. Arthritis Rheum 2013; 65 (Suppl):1775.
72. Anyanwu C, Langenhan J, Werth VP. Measurement of disease severity in cutaneous autoimmune diseases. F1000Prime Rep 2013; 5:19.
73. Goreshi R, Okawa J, Rose M, et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 2012; 132:1117-1124.
74. Klein RQ, Bangert CA, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887-894.
75. Goreshi R, Chock M, Foering K, et al. Quality of life in dermatomyositis. J Am Acad Dermatol 2011; 65:1107-1116.
76. Nabatian AS, Bashir MM, Wysocka M, et al. Tumor necrosis factor alpha release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. Arthritis Res Ther 2012; 14:R1.
77. Yassaee M, Fiorentino D, Okawa J, et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol 2010; 162:669-673.
78. Koenig M, Fritzler MJ, Targoff IN, et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9:R78.
79. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84:231-249.
80. Sultan SM, Ng KP, Edwards JC, et al. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008; 26:887-893.
81. Sultan SM, Allen E, Cooper RG, et al. Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis 2011; 70:1272-1276.
82. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002; 41:22-26.
83. Munoz-Beamud F, Isenberg DA. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol 2013; 31:896-903.
84. Sultan SM, Allen E, Oddis CV, et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 2008; 58:3593-3599.
85. Estephan B, Barohn RJ, Dimachkie MM, et al. Sporadic IBM: a case cohort. J Clin Neuromuscul Dis 2011; 12:18-19.
86. Muzyka I, Barohn RJ, Dimachkie MM, et al. Necrotizing autoimmune statinassociated myopathy. J Clin Neuromuscul Dis 2011; 12:17.
87. Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49:1713-1719.
88. Gono T, Kawaguchi Y, Kuwana M, et al. Brief report: Association of HLA-DRB1∗0101/∗0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 2012; 64:3736-3740.
89. Sugiura T, Kawaguchi Y, Goto K, et al. Positive association between STAT4 polymorphisms and polymyositis/dermatomyositis in a Japanese population. Ann Rheum Dis 2012; 71:1646-1650.
90. Rojana-udomsart A, James I, Castley A, et al. High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes. J Neuroimmunol 2012; 250:77-82.
91. Rojana-udomsart A, Mitrpant C, James I, et al. Analysis of HLA-DRB3 alleles and supertypical genotypes in the MHC Class II region in sporadic inclusion body myositis. J Neuroimmunol 2013; 254:174-177.
92. Rojana-udomsart A, Needham M, Luo YB, et al. The association of sporadic inclusion bodymyositis and Sjogren's syndromein carriers ofHLA-DR3and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg 2011; 113:559-563.
93. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79:1056-1060.
94. Mastaglia FL, Needham M, Scott A, et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord 2009; 19:763-765.
95. Scott AP, Laing NG, Mastaglia F, et al. Investigation of NOTCH4 coding region polymorphisms in sporadic inclusion body myositis. J Neuroimmunol 2012; 250:66-70.
96. Greenfield J, Hudson M, Pineau CA, et al., Canadian Scleroderma Research Group, Canadian Inflammatory Myopathy Study Group. Health-related quality of life (HRQoL) across systemic autoimmune rheumatic diseases (SARDs). J Rheumatol 2014 (in press).
97. Broten L, Avina-Zubieta JA, Lacaille D, et al. Systemic autoimmune rheumatic disease prevalence in Canada: updated analyses across 7 provinces. J Rheumatol 2014; 41:673-679.
98. Robinson AB, Hoeltzel MF, Wahezi DM, et al. Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken) 2014; 66:404-410.
99. Huber AM, Robinson AB, Reed AM, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) 2012; 64:546-553.
100. Hoeltzel MF, Becker ML, Robinson AB, et al. Race is a risk factor for calcinosis in patients with JDM: early results from the CARRAnet registry study [abstract]. Pediatr Rheumatol Online J 2012; 10 (Suppl 1):A65.
101. Bode RK, Klein-Gitelman MS, Miller ML, et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49:7-15.
102. Rouster-Stevens KA, Ferguson L, Morgan G, et al. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2014; 66:783-787.
103. Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62:1446-1451.
104. Pachman LM, Abbott K, Sinacore JM, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148:247-253.
105. Kim E, Cook-Mills J, Morgan G, et al. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheum 2012; 64:3809-3817.
106. Wang M, Xie H, Shrestha S, et al. Methylation alterations of WT1 and homeobox genes in inflamed muscle biopsy samples from patients with untreated juvenile dermatomyositis suggest self-renewal capacity. Arthritis Rheum 2012; 64:3478-3485.
107. Urganus AL, Zhao YD, Pachman LM. Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. Arthritis Rheum 2009; 61:501-508.
108. Balboni I, Niewold TB, Morgan G, et al. Interferon-alpha induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum 2013; 65:2424-2429.
109. Niewold TB, Wu SC, Smith M, et al. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics 2011; 127:e1239-e1246.
110. Shah M, Mamyrova G, Targoff IN, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92:25-41.
111. Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92:223-243.
112. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-3689.
113. Bingham A, Mamyrova G, Rother KI, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008; 87:70-86.
114. Mamyrova G, O'Hanlon TP, Monroe JB, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006; 54:3979-3987.
115. Mamyrova G, O'Hanlon TP, Sillers L, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008; 58:3941-3950.
116. Shah M, Targoff IN, Rice MM, et al. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum 2013; 65:1934-1941.
117. Vegosen LJ, Weinberg CR, O'Hanlon TP, et al. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum 2007; 56:2719-2728.
118. Mamyrova G, Katz JD, Jones RV, et al. Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. Arthritis Care Res (Hoboken) 2013; 65:1969-1975.
119. Ruperto N, Ravelli A, Pistorio A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/ European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59:4-13.
120. Ruperto N, Pistorio A, Ravelli A, et al. The Pediatric Rheumatology International Trials Organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62:1533-1541.
121. Hasija R, Pistorio A, Ravelli A, et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum 2011; 63:3142-3152.
122. Lazarevic D, Pistorio A, Palmisani E, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013; 72:686-693.
123. Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011; 63 (Suppl 11):S118-S157.
124. Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62:465-472.
125. Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50:1595-1603.
126. Huber AM, Hicks JE, Lachenbruch PA, et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001; 28:1106-1111.
127. Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50:2281-2290.
128. Huber AM, Dugan EM, Lachenbruch PA, et al. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007; 46:1606-1611.
129. McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45:1255-1260.
130. Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther 2013; 15:211.
131. Tansley SL, Betteridge DJ, Shaddick G, et al., on behalf of the Juvenile Dermatomyositis Research Group. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology 2014. [Epub ahead of print]
132. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60:1807-1814.
133. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47:877-880.
134. Varsani H, Charman SC, Li CK, et al. Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Ann Rheum Dis 2013. [Epub ahead of print]
135. Chinoy H, Platt H, Lamb JA, et al. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum 2008; 58:3247-3254.
136. Nistala K, Varsani H, Wittkowski H, et al. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Res Ther 2013; 15:R131.
137. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25:1198-1204.
138. Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49:300-305.
139. Pachman LM, Hayford JR, Hochberg MC, et al. New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40:1526-1533.
140. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43:2368-2377.
141. Pachman LM, Lipton R, Ramsey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005; 53:166-172.
142. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1∗0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002; 168:4154-4163.
143. Fedczyna TO, Lutz J, Pachman LM. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clin Immunol 2001; 100:236-239.
144. Sato JO, Sallum AM, Ferriani VP, et al. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 2009; 27:1031-1038.
145. Sanner H, Kirkhus E, Merckoll E, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a casecontrol study. Arthritis Care Res (Hoboken) 2010; 62:1103-1111.
146. Sanner H, Aalokken TM, Gran JT, et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011; 70:86-91.
147. Schwartz T, Sanner H, Gjesdal O, et al. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis 2013. [Epub ahead of print]
148. Sanner H, Gran JT, Sjaastad I, Flato B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009; 48:1541-1547.
149. Sanner H, Sjaastad I, Flatø B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Pediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 2014; 53:1578-1585.
150. Mathiesen PR, Orngreen MC, Vissing J, et al. Aerobic fitness after JDM: a long-term follow-up study. Rheumatology (Oxford) 2013; 52:287-295.
151. Mathiesen P, Hegaard H, Herlin T, et al. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 2012; 41:50-58.
152. Mathiesen PR, Zak M, Herlin T, Nielsen SM. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol 2010; 28:782-789.
153. Mathiesen PR, Buchvald F, Nielsen KG, et al. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. Rheumatology (Oxford) 2014; 53:644-649.
154. Kishi T, Miyamae T, Hara R, et al. Clinical analysis of 50 children with juvenile dermatomyositis. Mod Rheumatol 2013; 23:311-317.
155. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther 2011; 13:209.
156. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52:2607-2615.
157. Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011; 70:427-436.
158. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65:314-324.
159. Rider LG, Lachenbruch PA, Monroe JB, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009; 60:3425-3435.
160. Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010; 62:63-72.
161. Chinoy H, Lamb JA, Ollier WE, Cooper RG. Recent advances in the immunogenetics of idiopathic inflammatory myopathy. Arthritis Res Ther 2011; 13:216.
162. O'Hanlon TP, Rider LG, Mamyrova G, et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006; 54:3670-3681.
163. Rider LG, Wu L, Mamyrova G, et al. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2010; 49:2381-2390.
164. Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011; 13:249.
165. Scully MA, Cwik VA, Marshall BC, et al. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Neurology 2013; 80:583-589.
166. Vaught J, Lockhart NC. The evolution of biobanking best practices. Clin Chim Acta 2012; 413:1569-1575.